Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Role of HNKs in Ketamine Antidepressant Effect
NCT03977675Phase 1Terminated
- Sponsor
- Columbia University
- Start
- May 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ketamine in major depressive disorder (MDD) (3 arms), sponsored by Columbia University. Primary endpoints: Change in HNK Plasma Concentration and Change in DHNK Plasma Concentration. Started May 2019; status: terminated.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03977675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03977675.